Decoy Therapeutics (NASDAQ:DCOY) Shares Down 13% – Time to Sell?

Posted by James Conley on Nov 1st, 2026

Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) fell 13% during trading on Friday. The stock traded as low as $1.05 and last traded at $1.07. Approximately 116,927 shares were traded during trading, an increase of 43% from the average daily volume of 81,917 shares. The stock had previously closed at $1.23.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Decoy Therapeutics in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $30.00.

Read Our Latest Report on DCOY

Decoy Therapeutics Stock Performance

The company’s 50-day moving average price is $2.16 and its two-hundred day moving average price is $5.39. The stock has a market cap of $2.56 million, a PE ratio of -0.04 and a beta of 0.65.

Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($4.46) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter. Equities research analysts forecast that Decoy Therapeutics will post -8.96 earnings per share for the current fiscal year.

Decoy Therapeutics Company Profile

(Get Free Report)

Decoy Therapeutics is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms.

The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies.

Publicly available information about Decoy Therapeutics’ operating history, geographic presence and leadership is limited.